AstraZeneca finally drops roxadustat US rights after FDA rejection, trial failure

AstraZeneca and FibroGen have finally reached the end of the road for their U.S. collaboration on the oral anemia drug roxadustat.

More than two years after a high-profile FDA rejection, AstraZeneca has returned rights to the HIF-PH inhibitor in the U.S. and certain other countries but retained an interest in China and South Korea, where the drug is approved under the brand name Evrenzo.